Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)31266-5
Abstract: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2 (SGLT2), reduced the risk of hospitalization for heart failure or cardiovascular death in type 2 diabetic patients. The mechanism by which EMPA induces cardiovascular…
read more here.
Keywords:
inhibitor sodium;
selective inhibitor;
cardioprotective anti;
sodium glucose ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "RSC Advances"
DOI: 10.1039/d1ra08320a
Abstract: This study was conducted to explore the potential cardioprotective and anti-depressive effects of dichloromethane (DCM) fractions of Morus macroura leaves (L) and stem branches (S) on post-myocardial infarction (MI) depression induced by isoprenaline (ISO) in…
read more here.
Keywords:
cardioprotective anti;
depressive effects;
depression;
morus macroura ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Clinical science"
DOI: 10.1042/cs20220874
Abstract: Previous studies of the Caveolin 1 (Cav1) protein and caveolae, which are lipid raft structures found on the plasma membranes of certain cells, are associated with fat metabolism disorders, inflammation, diabetes and cardiovascular disease. However,…
read more here.
Keywords:
cardioprotective anti;
cav1;
effects caveolin;
anti inflammatory ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Journal of cardiovascular pharmacology"
DOI: 10.1097/fjc.0000000000001436
Abstract: ABSTRACT Angina pectoris remains a significant burden despite advances in medical therapy and coronary revascularization. Many patients (up to 30%) with angina have normal coronary arteries, with coronary microvascular disease (CMD) and/or coronary artery vasospasm…
read more here.
Keywords:
cardioprotective anti;
review;
efficacy;
anginal efficacy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e23057
Abstract: e23057 Background: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular death in type 2 diabetic patients. We aimed to study if…
read more here.
Keywords:
cardioprotective anti;
effects doxorubicin;
doxo;
inflammatory effects ... See more keywords